EGFR (Ab-1026) Antibody

What is the EGFR (Ab-1026) Antibody and what epitope does it recognize?

The EGFR (Ab-1026) Antibody is a rabbit polyclonal antibody specifically generated to recognize the phosphorylated serine residue at position 1026 in the C-terminal region of human EGFR. It is produced by immunizing rabbits with a KLH-conjugated synthetic peptide spanning amino acids 1004-1033 from the C-terminal region of human EGFR. This antibody targets the human EGFR protein (accession number P00533, gene ID 1956) and provides a tool for studying specific phosphorylation events in the EGFR signaling pathway .

What are the validated experimental applications for this antibody?

Based on manufacturer validation data, the EGFR (Ab-1026) Antibody has been successfully employed in multiple experimental techniques:

The versatility across multiple applications makes this antibody suitable for complementary approaches in EGFR research, allowing researchers to validate findings through different methodological approaches .

What is the optimal protocol for detecting EGFR S1026 phosphorylation by Western blotting?

For optimal detection of EGFR S1026 phosphorylation by Western blotting, researchers should implement the following methodology:

• Sample preparation: Prepare cell lysates in a buffer containing phosphatase inhibitors to preserve phosphorylation states. Typically, 35 μg of total protein per lane is sufficient for detection.

• Antibody application: Dilute the EGFR (Ab-1026) Antibody at 1:1000 in appropriate blocking buffer. For secondary detection, a goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution has been validated.

• Controls: Include positive controls such as lysates from EGF-stimulated A431 cells, which express high levels of EGFR and show detectable S1026 phosphorylation.

• Signal interpretation: The expected molecular weight for EGFR is approximately 170 kDa. When analyzing blots, compare phospho-specific signals to total EGFR levels to normalize for expression variations.

This protocol has been validated with several cell lines including A431, HUVEC, and PC-3, which represent different tissue origins and EGFR expression levels .

How should researchers design experiments to correlate EGFR S1026 phosphorylation with receptor activation and downstream signaling?

To effectively correlate EGFR S1026 phosphorylation with receptor activation and downstream signaling, researchers should implement a multi-faceted experimental design:

• Dose-response analysis: Treat cells with increasing concentrations of EGF (0-100 ng/ml) and analyze both S1026 phosphorylation and canonical tyrosine phosphorylation sites (e.g., Y1068) to establish activation thresholds.

• Time-course experiments: Monitor S1026 phosphorylation at different time points (0-120 minutes) after EGF stimulation to determine temporal relationship with tyrosine phosphorylation and downstream pathway activation.

• Inhibitor studies: Use specific inhibitors of various kinases to identify potential mediators of S1026 phosphorylation, which may differ from those responsible for tyrosine phosphorylation.

• Quantitative analysis: Apply ELISA-based techniques such as Dissociation Enhanced Lanthanide Fluoroimmunoassay technology to quantitatively measure phosphorylation levels across experimental conditions .

• Mathematical modeling: Consider implementing models like the Multiple Phosphorylation Model (MPM) or Early Activation Model (EAM) described in the literature to interpret dynamic phosphorylation patterns .

This comprehensive approach will help establish whether S1026 phosphorylation follows similar activation patterns as tyrosine phosphorylation or represents a distinct regulatory mechanism.

What positive and negative controls are essential when using this antibody?

Rigorous control selection is critical for generating reliable and interpretable data with the EGFR (Ab-1026) Antibody:

These controls collectively ensure that observed signals truly represent specific S1026 phosphorylation and provide context for proper data interpretation across different experimental conditions .

How can researchers investigate the relationship between EGFR S1026 phosphorylation and receptor ubiquitination?

Investigating the relationship between EGFR S1026 phosphorylation and receptor ubiquitination requires sophisticated experimental approaches that capture the dynamic and potentially threshold-dependent relationship between these post-translational modifications:

• Quantitative correlation analysis: Use ELISA-based assays to simultaneously measure S1026 phosphorylation and ubiquitination levels across EGF concentration gradients. This approach allows researchers to determine if these modifications follow similar threshold dynamics or occur at different activation levels .

• Temporal sequence determination: Perform time-course experiments with short intervals (0-30 minutes) after EGF stimulation to establish whether S1026 phosphorylation precedes, coincides with, or follows ubiquitination.

• Mechanistic investigation: Examine whether S1026 phosphorylation affects recruitment of ubiquitination machinery components (e.g., Cbl, Grb2) through co-immunoprecipitation experiments using the EGFR (Ab-1026) Antibody .

• Mutational analysis: Generate EGFR S1026A (phospho-deficient) and S1026D (phospho-mimetic) mutants to directly assess the impact of this phosphorylation site on receptor ubiquitination patterns and kinetics.

• Mathematical modeling: Apply the EAM model described in the literature to interpret how variations in receptor levels and activation might influence the relationship between phosphorylation and ubiquitination thresholds .

This research direction could provide valuable insights into whether S1026 phosphorylation serves as a regulatory node in determining EGFR trafficking and degradation decisions.

What is the role of EGFR S1026 phosphorylation in nuclear EGFR signaling?

Nuclear EGFR signaling represents an emerging area of EGFR biology where S1026 phosphorylation may play a significant role. To investigate this connection, researchers should consider:

• Nuclear localization analysis: Perform cell fractionation followed by Western blotting with EGFR (Ab-1026) Antibody to determine if S1026-phosphorylated EGFR preferentially localizes to the nucleus compared to total EGFR.

• Transcriptional partner interactions: Investigate whether S1026 phosphorylation affects EGFR interaction with known nuclear partners such as STAT3, STAT5A, E2F1, DNA-PK, PCNA, or RNA helicase A through co-immunoprecipitation experiments .

• Target gene regulation: Assess if S1026 phosphorylation status correlates with expression of known nuclear EGFR target genes such as iNOS, cyclin D1, and B-Myb through RT-qPCR and ChIP assays .

• DNA binding capacity: Examine whether S1026 phosphorylation influences EGFR binding to AT-rich sequences (ATRS) in target gene promoters through ChIP experiments coupled with EGFR (Ab-1026) Antibody detection .

This research direction could identify unique roles for S1026 phosphorylation in nuclear EGFR functions, which remain less well characterized than canonical membrane signaling pathways.

How does EGFR S1026 phosphorylation relate to resistance mechanisms against EGFR-targeted therapies?

Understanding how S1026 phosphorylation might contribute to therapeutic resistance represents a clinically important research application:

• Clinical correlation studies: Analyze patient samples before and after developing resistance to EGFR tyrosine kinase inhibitors (TKIs), comparing S1026 phosphorylation patterns between responders and non-responders.

• In vitro resistance modeling: Develop resistant cell lines through long-term exposure to EGFR inhibitors (e.g., gefitinib, canertinib) and compare S1026 phosphorylation between parental and resistant lines. The literature indicates that irreversible inhibitors like canertinib may overcome certain resistance mechanisms .

• Signaling pathway analysis: Determine if S1026 phosphorylation can maintain activation of downstream pathways (MAPK, AKT) when canonical EGFR signaling is blocked by inhibitors. Research has shown that these pathways are critical for the efficacy of EGFR inhibitors in various cancer types .

• Combination therapy evaluation: Test whether inhibitors of kinases responsible for S1026 phosphorylation might synergize with EGFR TKIs, potentially overcoming resistance mechanisms.

This research could potentially identify S1026 phosphorylation as a biomarker for resistance or as a novel therapeutic target to overcome resistance to existing EGFR therapies.

What are common challenges in detecting EGFR S1026 phosphorylation and how can they be addressed?

Researchers often encounter technical challenges when working with phospho-specific antibodies like EGFR (Ab-1026) Antibody. The following table outlines common issues and proven solutions:

Addressing these challenges requires methodical optimization of each step in the experimental workflow, with particular attention to preserving phosphorylation states throughout sample processing .

How should researchers quantitatively analyze EGFR S1026 phosphorylation in relation to total EGFR and other phosphorylation sites?

Rigorous quantitative analysis of EGFR phosphorylation requires methodological approaches that account for expression variation and allow comparison across different phosphorylation sites:

• Western blot-based quantification:

  • Perform parallel blots for S1026 phosphorylation, other phospho-sites, and total EGFR

  • Use digital image analysis software to measure band intensities

  • Calculate phospho-to-total EGFR ratios for each phosphorylation site

  • Include standard curves if absolute quantification is needed

• ELISA-based quantification:

  • Implement Dissociation Enhanced Lanthanide Fluoroimmunoassay technology as described in the literature

  • Prepare lysates in RIPA/1% SDS buffer and dilute to 0.2% SDS before incubation

  • Run parallel assays for different phosphorylation sites and total EGFR

  • Calculate normalized phosphorylation ratios across experimental conditions

• Mathematical modeling approaches:

  • Apply models like the Multiple Phosphorylation Model (MPM) to interpret dynamics

  • Use the Early Activation Model (EAM) to understand threshold behaviors

  • Incorporate parameters from experimental data to refine model predictions

• Statistical analysis:

  • Apply appropriate statistical tests to determine significance of observed changes

  • Consider biological variability versus technical variability

  • For dose-response studies, calculate EC50 values and compare them across conditions

These quantitative approaches enable meaningful comparisons of S1026 phosphorylation with better-characterized tyrosine phosphorylation sites in EGFR signaling.

How can mathematical models help interpret experimental data on EGFR S1026 phosphorylation?

Mathematical modeling offers powerful tools for understanding complex EGFR signaling dynamics that may not be apparent from experimental data alone:

• Available modeling frameworks:

  • The Multiple Phosphorylation Model (MPM) tracks EGFR phosphorylation states

  • The MPM-B model incorporates binding of downstream effectors

  • The Early Activation Model (EAM) includes EGFR activation mechanisms like receptor dimerization

• Model adaptation for S1026 research:

  • Existing models can be modified to include serine phosphorylation sites alongside tyrosine sites

  • Parameters should be experimentally constrained when possible, rather than simply fitting to data

  • Models can help interpret how S1026 phosphorylation relates to receptor activation thresholds

• Predictive applications:

  • Models can predict how varying EGFR expression levels affect S1026 phosphorylation thresholds

  • Simulation studies can anticipate the effects of inhibitors on phosphorylation patterns

  • Sensitivity analysis can identify key parameters affecting S1026 phosphorylation

Mathematical models are particularly valuable for understanding threshold behaviors in EGFR signaling, as demonstrated by research showing that total EGFR levels affect the position of signaling thresholds .

What emerging research areas could benefit from studying EGFR S1026 phosphorylation?

Several cutting-edge research areas represent promising directions for investigators studying EGFR S1026 phosphorylation:

• Crosstalk with non-canonical signaling pathways:

  • Investigate interactions between S1026 phosphorylation and other receptor tyrosine kinases

  • Explore connections with stress response pathways and cellular metabolism

  • Examine links to inflammatory signaling networks

• Single-cell analysis of phosphorylation heterogeneity:

  • Apply flow cytometry and imaging approaches to study cell-to-cell variation in S1026 phosphorylation

  • Correlate S1026 phosphorylation patterns with cellular phenotypes at the single-cell level

  • Investigate how phosphorylation heterogeneity relates to differential responses to EGFR-targeted therapies

• Development of therapeutic strategies targeting non-tyrosine phosphorylation:

  • Explore kinase inhibitors that specifically affect S1026 phosphorylation

  • Investigate combination therapies targeting both tyrosine and serine/threonine phosphorylation

  • Develop phospho-S1026-specific antibody therapeutics or diagnostic tools

• Structural biology of phosphorylated EGFR:

  • Determine how S1026 phosphorylation affects EGFR conformation and interaction surfaces

  • Investigate whether this modification influences receptor dimerization or clustering

  • Examine effects on binding of therapeutic antibodies or small molecules

These research directions could establish S1026 phosphorylation as an important regulatory node in EGFR biology with potential therapeutic implications.